Does Nucleos(t)ide (NUC) Analogs Therapy in Hepatitis B Impact the Incidence of Liver Cancer?

Walid S. Ayoub, Paul Martin, Pietro Lampertico

Research output: Contribution to journalReview articlepeer-review


Hepatocellular carcinoma (HCC) is a major source of mortality. It is the second most common cause of death worldwide, the fifth most common cancer in men, and ninth in women. It is estimated that 782,000 cases are diagnosed annually, of which half occurs on China [1]. It is more prevalent in Eastern and South-Eastern Asia and less prevalent in the USA and Northern Europe [2]. It carries a high burden on society and significantly impairs quality of life. It is estimated that up to 746,000 deaths occurs annually from hepatocellular carcinoma with approximately half of the death associated with hepatitis B [2]. Fortunately, an increasing body of evidence confirms the efficacy of HBV vaccination and antiviral therapy in reducing the incidence of HCC. In this review, we address treatment of hepatitis B and its impact on development of HCC.

Original languageEnglish (US)
Pages (from-to)279-283
Number of pages5
JournalCurrent Hepatitis Reports
Issue number4
StatePublished - Jan 1 2015


  • Entecavir
  • Hepatitis B
  • Hepatocellular carcinoma
  • Lamivudine
  • Liver cancer
  • Nucleos(t)ides
  • Tenofovir

ASJC Scopus subject areas

  • Hepatology
  • Virology


Dive into the research topics of 'Does Nucleos(t)ide (NUC) Analogs Therapy in Hepatitis B Impact the Incidence of Liver Cancer?'. Together they form a unique fingerprint.

Cite this